Tag Archives: drug
Novel drug treatment for human infection with H7N9- avian influenza A
The H7N9 subtype of avian influenza is an enzootic and airborne virus which caused an influenza outbreak in China. Infected individuals mostly worked with poultry, suggesting H7N9 virus-infected poultry as the primary source of human infection. Significantly
Tumor regression in a high-mortality mouse pancreatic cancer (xenograft) model with aminosteroid RM-581
Pancreatic cancer is classified as a high-mortality cancer with a five-year relative survival rate of only 9%. Although most cancer type survival rates have improved over the past decades, pancreatic cancer morbidity has been stable, which illustrates
Production techniques for the development of sub-micron size polymeric drug delivery formulations evaluated
Polymeric drug delivery formulations containing active pharmaceutical ingredients (APIs) offer the advantages of improved stability, targeted delivery and controlled release of APIs in vivo, which can reduce drug burden while enhancing efficacy. Poly(lactic-co-glycolic acid) (PLGA) is amongst
Suicide and drug overdose mortality in Australian young males as a socioeconomic malady
When mortality trends in Australian young adult (20–34 year) males are analysed over 1979–2011, some interesting features emerge. First, a decline in motor vehicle accident mortality by half between 1980 and 1998 did not translate into reduced
Should we think that neem gum polysaccharide and their semi-synthetic derivatives can be utilized as carrier for nanoformulation
One of the major concerns related to the newly synthesized drug is poor water solubility, which seems to be a major concern for the pharmaceutical manufacturer and also a rate limiting step in the bioavailability. In this
How we can curb deaths from heroin use
Evidence from many countries shows an alarmingly high death rate amongst former prisoners with histories of heroin addiction in the two weeks following their prison release. A heroin overdose is the most common cause of death in
Heparan sulphate; inspiration for new leishmaniasis drugs
Leishmaniasis is a group of tropical parasitic diseases caused by infection with the protozoan parasite Leishmania and is endemic in 98 countries, with approximately 2 million new cases annually. Infection occurs when someone is bitten by an
Rethinking drugs’ development in acute heart failure?
Acute heart failure (AHF) affects 1-2% of adults in developed countries. It strikes mainly people above the age 60, peeking in those older than 85 (prevalence ~ 17.4%). AHF is a life threatening medical event, with gradual
International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems. Osaka, Japan. September 09-10, 2019
Cientific Group is overpowered to declare its absolute first “International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems”. Pharma Conferences hung on September 09-10, 2019 at Osaka, Japan. Pharmaceutica – 2019 gives a general stage
Cellular stress and AMPK activators including metformin and the anesthetic drug propofol promote restoration of human consciousness
The neural mechanisms that give rise to human consciousness have been described as one of the greatest and most profound mysteries in all of modern medicine. The use of general anesthetics to induce loss of consciousness (LOC)
Bacteriocin AS-48: a potent drug against sleeping sickness
African trypanosomiasis has been a historical scourge on the African continent and one of the major causes of poverty. It is responsible for sleeping sickness in humans (HAT), and it avoids the development of agriculture based on
International Conference on Pharmaceutical Sciences and Drug delivery. Milan, Italy. November 18-19, 2019
Theme: Optimizing Research reforms of the Pharmaceutical Industry. We cordially invite each and every interested and enthusiastic participant from all over the world to take part in the International Conference on Pharmaceutical Sciences and Drug delivery, at
Advances in drug discovery and development in geriatric psychiatry
Drug discovery for disorders of the central nervous system is a long and challenging process, with a high attrition rate from the preclinical stages through to marketing a compound. In geriatric psychiatry, the heterogeneous nature of these
Lernaean hydra puzzle in compensatory angiogenesis and tumor drug resistance
Before we proceed to apply the analogy of Lernaean hydra to compensatory angiogenesis and tumor drug resistance against anti-angiogenic drugs (AADs), let us have a cursory look at the interesting mythology of this hydra. According to Greek
A drug resistance gene mediates stringent response in bacteria
Mycobacteria represent an important group of bacteria. Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), infects about a third of the world population, of which 5% to 15% develop active disease. Furthermore, a rapid emergence of multidrug
Statins: Good for the heart, but do they impact the brain?
High cholesterol, termed hyperlipidemia, is a risk factor for cardiovascular disease. Therefore, keeping cholesterol levels low through diet and exercise has proven benefits for reducing heart disease risk. For adults who cannot meet their cholesterol targets through
Compounded medication for patients with rare diseases
Pharmaceutical compounding is the preparation of unlicensed medicines in order to meet specific patient needs that do not have a licensed (commercial) medicine available on the market. Especially for patients with rare diseases it is complementary when
A new strategy to drug development for neuromuscular disorder
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a neurodegenerative disease in which motor neuron (MN) loss in both the spinal cord and motor cortex causes progressive paralysis, muscle atrophy, and death. So far,
Estimating effects of new psychoactive substances (NPS) based on in vitro neurotoxicity data
The use of new psychoactive substances (NPS) is increasing and currently > 600 NPS have been reported. However, limited information on neuropharmacological and toxicological effects of NPS is available, hampering risk characterization. We reviewed the literature on
A new strategy to deliver anti-cancer nanodrugs and decrease their toxic side effects by temporarily blunting the RES uptake using Intralipid®
Nanodrugs, or nanotechnology-based therapeutics, show great promise for treating a number of diseases, including cancer. However, an analysis of the literature from the past 10 years finds that in studies of cancer nanodrugs, a very small fraction
